title: Targeting CXCR7/ACKR3 as a therapeutic strategy to promote remyelination in the adult central nervous system.
abstract: Current treatment modalities for the neurodegenerative disease multiple sclerosis (MS) use disease-modifying immunosuppressive compounds but do not promote repair. Although several potential targets that may induce myelin production have been identified, there has yet to be an approved therapy that promotes remyelination in the damaged central nervous system (CNS). Remyelination of damaged axons requires the generation of new oligodendrocytes from oligodendrocyte progenitor cells (OPCs). Although OPCs are detected in MS lesions, repair of myelin is limited, contributing to progressive clinical deterioration. In the CNS, the chemokine CXCL12 promotes remyelination via CXCR4 activation on OPCs, resulting in their differentiation into myelinating oligodendrocytes. Although the CXCL12 scavenging receptor CXCR7/ACKR3 (CXCR7) is also expressed by OPCs, its role in myelin repair in the adult CNS is unknown. We show that during cuprizone-induced demyelination, in vivo CXCR7 antagonism augmented OPC proliferation, leading to increased numbers of mature oligodendrocytes within demyelinated lesions. CXCR7-mediated effects on remyelination required CXCR4 activation, as assessed via both phospho-S339-CXCR4-specific antibodies and administration of CXCR4 antagonists. These findings identify a role for CXCR7 in OPC maturation during remyelination and are the first to use a small molecule to therapeutically enhance myelin repair in the demyelinated adult CNS.
authors.affiliation: Department of Internal Medicine, 2 Department of Pathology and Immunology, and 3 Department of Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, MO 63110.
authors.forename: Jessica L
authors.initials: JL
authors.lastname: Williams
authors.forename: Jigisha R
authors.initials: JR
authors.lastname: Patel
authors.forename: Brian P
authors.initials: BP
authors.lastname: Daniels
authors.forename: Robyn S
authors.initials: RS
authors.lastname: Klein
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001369:Axons / Q000378:metabolism; D001596:Benzylamines; D015153:Blotting, Western; D001973:Bromodeoxyuridine; D002490:Central Nervous System / Q000166:cytology / Q000378:metabolism / Q000502:physiology*; D000080027:Cyclams; D006571:Heterocyclic Compounds; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009186:Myelin Sheath / Q000378:metabolism / Q000502:physiology*; D009836:Oligodendroglia / Q000166:cytology / Q000378:metabolism / Q000502:physiology*; D060888:Real-Time Polymerase Chain Reaction; D054387:Receptors, CXCR / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D019718:Receptors, CXCR4 / Q000378:metabolism; D013234:Stem Cells / Q000166:cytology / Q000502:physiology*
chemical_list: D001596:Benzylamines; C514936:CXCR4 protein, mouse; C501897:Cmkor1 protein, mouse; D000080027:Cyclams; D006571:Heterocyclic Compounds; D054387:Receptors, CXCR; D019718:Receptors, CXCR4; D001973:Bromodeoxyuridine; C088327:plerixafor
references.citation: J Exp Med. 2011 Feb 14;208(2):327-39
references.pmid: 21300915
references.citation: Eur J Neurosci. 2003 Sep;18(6):1593-606
references.pmid: 14511338
references.citation: J Neurosci. 1998 Jan 15;18(2):601-9
references.pmid: 9425002
references.citation: Acta Neuropathol. 2012 Dec;124(6):847-60
references.pmid: 22933014
references.citation: J Neuroimmunol. 2006 Aug;177(1-2):27-39
references.pmid: 16782208
references.citation: PLoS One. 2010 Feb 11;5(2):e9175
references.pmid: 20161793
references.citation: Nature. 1998 Jun 11;393(6685):595-9
references.pmid: 9634238
references.citation: J Immunol. 2006 Dec 1;177(11):8053-64
references.pmid: 17114479
references.citation: Lancet. 2002 Apr 6;359(9313):1221-31
references.pmid: 11955556
references.citation: Trends Immunol. 2004 Jun;25(6):306-14
references.pmid: 15145320
references.citation: Glia. 2005 May;50(3):258-69
references.pmid: 15756692
references.citation: J Neuroinflammation. 2011 Dec 06;8:170
references.pmid: 22145790
references.citation: Glia. 2011 Dec;59(12):1813-21
references.pmid: 21830237
references.citation: Small. 2013 Feb 25;9(4):585-95
references.pmid: 23109183
references.citation: FEBS Lett. 2002 Sep 11;527(1-3):255-62
references.pmid: 12220670
references.citation: Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11068-73
references.pmid: 20534452
references.citation: Development. 2009 Jun;136(11):1919-28
references.pmid: 19429788
references.citation: Ann Neurol. 2010 Dec;68(6):915-24
references.pmid: 21154415
references.citation: Brain. 2008 Jul;131(Pt 7):1749-58
references.pmid: 18515322
references.citation: Nat Rev Immunol. 2009 Jun;9(6):440-7
references.pmid: 19444308
references.citation: Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18117-22
references.pmid: 15608062
references.citation: J Neurochem. 1999 Dec;73(6):2348-57
references.pmid: 10582593
references.citation: Neuropathol Appl Neurobiol. 2008 Feb;34(1):105-14
references.pmid: 17961136
references.citation: Nat Rev Neurosci. 2008 Nov;9(11):839-55
references.pmid: 18931697
references.citation: N Engl J Med. 2002 Jan 17;346(3):165-73
references.pmid: 11796850
references.citation: J Neurosci. 2000 Sep 1;20(17):6404-12
references.pmid: 10964946
references.citation: Cell. 2008 Feb 8;132(3):463-73
references.pmid: 18267076
references.citation: Am J Pathol. 1997 Apr;150(4):1253-66
references.pmid: 9094982
references.citation: Am J Pathol. 2008 Mar;172(3):799-808
references.pmid: 18276777
references.citation: Nat Neurosci. 2001 Nov;4(11):1116-22
references.pmid: 11600888
references.citation: Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11062-7
references.pmid: 20534485
references.citation: J Neuroimmunol. 2008 Jul 31;198(1-2):39-45
references.pmid: 18513805